Healthcare
Live Price
Offline$185.74
+1.49% today
1Y Change
+25.90%
Window
Jun 26, 2025 → Jun 22, 2026
Coverage: 247 bars · Jun 26, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AstraZeneca PLC (AZN) is a Healthcare stock with a market cap of $281.40B. The stock last traded around $185.74 and up 25.9% across the available one-year price window (Jun 26, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of +190.7%, a dividend yield of 1.8%. What stands out right now is revenue +8.6%, EPS +190.7%, free cash flow +61.7% with operating margin 23.5% and ROIC 12.9%. The dividend is present but secondary, with a yield around 1.8%. Valuation sits in the middle of the pack at P/E 26.9 and price/sales 4.6. Stock Foundry combines AZN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AZN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AZN Max Drawdown
-16.49%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AZN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.4B
-15.6% YoY
FY Net Income
$112.0M
-96.6% YoY
Free Cash Flow
$3.8B
-48.0% YoY
Revenue Growth
+8.6%
EPS Growth
+190.7%
Gross Margin
79.7%
Net Margin
17.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 58.7B | 54.1B | 45.8B | 44.4B | 37.4B |
| Gross Profit | 48.1B | 43.9B | 37.5B | 32.0B | 25.0B |
| Operating Income | 13.7B | 10.0B | 8.2B | 3.8B | 1.1B |
| EBITDA | 19.8B | 15.4B | 13.4B | 9.1B | 5.1B |
| Net Income | 10.3B | 7.0B | 6.0B | 3.3B | 112M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.7B | 5.5B | 5.8B | 6.2B | 6.3B |
| Total Assets | 114.1B | 104.0B | 101.1B | 96.5B | 105.4B |
| Total Liabilities | 65.4B | 63.2B | 62.0B | 59.4B | 66.1B |
| Shareholder Equity | 48.7B | 40.8B | 39.1B | 37.0B | 39.3B |
| Total Debt | 29.7B | 30.1B | 28.6B | 29.1B | 30.7B |
| Net Debt | 24.0B | 24.6B | 22.8B | 23.0B | 24.4B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6.0B
-39.2% YoY
Capital Expenditures
2.2B
+14.4% YoY
Free Cash Flow
3.8B
-48.0% YoY
Key ratios
Gross Margin
79.7%
Operating Margin
23.5%
Net Margin
17.2%
ROE
22.4%
Debt / Equity
0.72x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.